
22 Jul MaxCyte
Cenk Sumen, Chief Technology Officer
Oct. 12 | 4:45pm | Oxford Biomedica Ballroom
Gaithersburg, MD
(NASDAQ: MXCT)
In-person Presentation
MaxCyte® is a leading provider of cell-engineering platform technologies and is responsible for helping to bring next‐generation cell-based therapies to life. The company’s technology is employed by leading drug developers worldwide, including 20 of the top 25 global biopharmaceutical companies. Our Flow Electroporation® technology and next-generation ExPERT™ platform enable our partners to accelerate, streamline, and improve the drug development process from the early stages of research to commercialization.